{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T01:33:56Z","timestamp":1770514436826,"version":"3.49.0"},"reference-count":15,"publisher":"Scientific Scholar","content-domain":{"domain":["jpalliativecare.com"],"crossmark-restriction":true},"short-container-title":["IJPC"],"abstract":"\nObjectives:<\/jats:title>\nPaclitaxel and docetaxel are two commonly used chemotherapeutic agents in the treatment of various types of cancers. However, debilitating taxane-induced arthralgia and myalgia are among the most common adverse reactions associated with taxanes, which has greatly influenced medical practitioners. Most of the mild and moderate analgesics were found to be less effective in the management of taxane induced pain. So we used flupirtine, a non-opioid analgesic, in the treatment of taxane-induced pain.<\/jats:p>\n<\/jats:sec>\n\nMaterials and Methods:<\/jats:title>\nIn this study, we analysed the baseline pain score and follow-up data of 60 patients receiving a taxane-based chemotherapy regimen. Baseline data of these study populations experiencing significant taxane-induced pain were compared with follow-up data after treating them with analgesic flupirtine (200 mg\/day). The baseline and follow-up data representing pain were assessed with the help of the Visual Analogue Scale (VAS), and the quality of life was determined using the Brief Pain Inventory (BPI) scale questionnaire.<\/jats:p>\n<\/jats:sec>\n\nResults:<\/jats:title>\nThe mean baseline and follow-up VAS score was compared using paired sample t<\/jats:italic>-test, which showed a significant reduction in taxane-induced pain after treatment with flupirtine (P<\/jats:italic> < 0.001). Similarly, the mean BPI score representing the quality of life before and after treatment with flupirtine was compared, and a notable improvement in quality of life was seen after treatment with flupirtine. The mean and follow-up data of aspartate aminotransferase and alanine aminotransferase levels of patients were also compared to assess the adverse drug reaction profile of the drug, and the analyzed data was found to be statistically insignificant (no significant liver toxicity) which indicates that drug can be used effectively for a period of <2 weeks.<\/jats:p>\n<\/jats:sec>\n\nConclusion:<\/jats:title>\nWe believe that flupirtine can be used as an effective analgesic in dire situations where patients require opioid analgesics for the management of taxane-induced pain, provided that the drug is given for <2 weeks to avoid drug-related hepatotoxicity.<\/jats:p>\n<\/jats:sec>","DOI":"10.25259\/ijpc_41_2021","type":"journal-article","created":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T06:41:25Z","timestamp":1634798485000},"page":"262-265","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Flupirtine in the Management of Taxane-induced Pain in Cancer Patients"],"prefix":"10.25259","volume":"28","author":[{"given":"Anusha","family":"Paul","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi, Kerala, India,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Abdul","family":"Razak","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi, Kerala, India,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ameya","family":"Binoy","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi, Kerala, India,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Padma Uma","family":"Devi","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi, Kerala, India,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keechilat","family":"Pavithran","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Amrita Institute of Medical Sciences and Research Centre, Kochi, Kerala, India,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","published-online":{"date-parts":[[2021,10,21]]},"reference":[{"key":"10.25259\/IJPC_41_2021\/ref-1","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.jpainsymman.2015.12.340","article-title":"Update on prevalence of pain in patients with cancer: Systematic review and meta-analysis","volume":"51","author":"van den Beuken-van Everdingen","year":"2016","journal-title":"J Pain Symptom Manage"},{"key":"10.25259\/IJPC_41_2021\/ref-2","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1007\/s00520-015-2743-4","article-title":"Pain in cancer patients: Pain assessment by patients and family caregivers and problems experienced by caregivers","volume":"23","author":"Ovayolu","year":"2015","journal-title":"Support Care Cancer"},{"key":"10.25259\/IJPC_41_2021\/ref-3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1517\/13543776.2016.1111872","article-title":"Taxane anticancer agents: A patent perspective","volume":"26","author":"Ojima","year":"2016","journal-title":"Expert Opin Ther Pat"},{"key":"10.25259\/IJPC_41_2021\/ref-4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s40944-016-0088-7","article-title":"Neoadjuvant chemotherapy followed by neoadjuvant concurrent chemoradiation for locally advanced breast cancer: A feasibility study and 10-year follow up results","volume":"14","author":"Kunheri","year":"2016","journal-title":"Indian J Gynecol Oncol"},{"key":"10.25259\/IJPC_41_2021\/ref-5","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1177\/1078155215627502","article-title":"Taxane-induced arthralgia and myalgia: A literature review","volume":"23","author":"Chiu","year":"2017","journal-title":"J Oncol Pharm Pract"},{"key":"10.25259\/IJPC_41_2021\/ref-6","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s00520-002-0405-9","article-title":"Managing taxane toxicities","volume":"11","author":"Markman","year":"2003","journal-title":"Support Care Cancer"},{"key":"10.25259\/IJPC_41_2021\/ref-7","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.3892\/ol.2012.651","article-title":"Proposed medications for taxane-induced myalgia and arthralgia","volume":"3","author":"Imai","year":"2012","journal-title":"Oncol Lett"},{"key":"10.25259\/IJPC_41_2021\/ref-8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1568009033333754","article-title":"Paclitaxel resistance: Molecular mechanism and pharmacologic manipulation","volume":"3","author":"Yusuf","year":"2003","journal-title":"Curr Cancer Drug Targets"},{"key":"10.25259\/IJPC_41_2021\/ref-9","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1055\/s-2007-994997","article-title":"Neuronal potassium channel opening with flupirtine","volume":"67","author":"Kornhuber","year":"1999","journal-title":"Fortschr Neurol Psychiatr"},{"key":"10.25259\/IJPC_41_2021\/ref-10","doi-asserted-by":"publisher","first-page":"113","DOI":"10.22270\/jddt.v3i6.705","article-title":"Flupirtine: A mini review","volume":"3","author":"Kumar","year":"2013","journal-title":"J Drug Deliv Ther"},{"key":"10.25259\/IJPC_41_2021\/ref-11","first-page":"67","article-title":"Analgesic efficacy and safety of oral flupirtine in the treatment of cancer pain","volume":"63","author":"Scheef","year":"1987","journal-title":"Postgrad Med J"},{"key":"10.25259\/IJPC_41_2021\/ref-12","doi-asserted-by":"publisher","first-page":"467","DOI":"10.22270\/jddt.v9i1-s.2350","article-title":"Concise review: Therapeutic potential of flupirtine maleate","volume":"9","author":"Yadav","year":"2019","journal-title":"J Drug Deliv Ther"},{"key":"10.25259\/IJPC_41_2021\/ref-13","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.3390\/ijms20061451","article-title":"Mechanisms of chemotherapy induced peripheral neuropathy","volume":"20","author":"Zajaczkowska","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.25259\/IJPC_41_2021\/ref-14","doi-asserted-by":"publisher","first-page":"172","DOI":"10.4103\/0970-9185.94833","article-title":"Flupirtine: Clinical pharmacology","volume":"28","author":"Harish","year":"2012","journal-title":"J Anaesthesiol Clin Pharmacol"},{"key":"10.25259\/IJPC_41_2021\/ref-15","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00401-009-0586-0","article-title":"Paclitaxel induces axonal microtubules polar reconfiguration and impaired organelle transport: Implications for the pathogenesis of paclitaxel-induced polyneuropathy","volume":"119","author":"Shemesh","year":"2010","journal-title":"Acta Neuropathol"}],"container-title":["Indian Journal of Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jpalliativecare.com\/flupirtine-in-the-management-of-taxane-induced-pain-in-cancer-patients\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jpalliativecare.com\/flupirtine-in-the-management-of-taxane-induced-pain-in-cancer-patients\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T07:23:45Z","timestamp":1679297025000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpalliativecare.com\/flupirtine-in-the-management-of-taxane-induced-pain-in-cancer-patients\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,21]]},"references-count":15,"alternative-id":["10.25259\/IJPC_41_2021"],"URL":"https:\/\/doi.org\/10.25259\/ijpc_41_2021","relation":{},"ISSN":["1998-3735","0973-1075"],"issn-type":[{"value":"1998-3735","type":"electronic"},{"value":"0973-1075","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10,21]]},"article-number":"262"}}